Clinical Trial VICCPHI1255


Phase 1 Safety, Pharmacokinetic and Pharmacodynamic Study of PF-02341066, a C-MET/HGFR Selective Tyrosine Kinase Inhibitor, Administered Orally to Patients with Advanced Cancer

Principal Investigator(s)

Vicki Keedy


  • Protocol No. VICCPHI1255
  • Open Date: 09/28/2013
  • Staging: Phase I
  • Age Group: Adults
  • Scope: National
  • Objective: Determine the safety profile of PF-02341066 including identification of dose limiting toxicity (DLT) and maximum tolerated dose (MTD).
  • Disease Sites: Phase I
  • Therapies: Molecular Targeted Agents / Immunotherapy / Biologics
  • Drugs: Crizotinib; PF-02341066; Rifampin
  • Participating Institutions: Vanderbilt University
  • National Clinical Trial ID: NCT00585195
  • Secondary Protocol No: A8081001



Learn More

You do not have JavaScript enabled. This site works better with JavaScript turned on.